© Cancer Research UK 2008 Registered charity number Prostate cancer – UK December 2009

© Cancer Research UK 2008 Registered charity number Table One: Number of new cases and rates of prostate cancer, UK, 2006 EnglandWalesScotlandN.IrelandUK Cases Males30,0242,1642, ,515 Crude rate per 100,000 population Males Age-standardised rate (European) per 100,000 population Males % CI

© Cancer Research UK 2008 Registered charity number Figure One: Number of new cases and rates of prostate cancer, by age, UK, 2006

© Cancer Research UK 2008 Registered charity number Figure Two: Age-standardised* incidence and mortality rates for prostate cancer by world regions, 2002 estimates * to the European standard population

© Cancer Research UK 2008 Registered charity number Figure Three: Age standardised* (European) incidence and mortality rates, prostate cancer in EU countries, 2006 estimates * to the European standard population

© Cancer Research UK 2008 Registered charity number Figure Four: Age standardised* (European) incidence and mortality rates, prostate cancer, males, GB, * to the European standard population

© Cancer Research UK 2008 Registered charity number Figure Five: Age-specific incidence rates, prostate cancer, Great Britain,

© Cancer Research UK 2008 Registered charity number Figure Six: Age-standardised* rates of transurethral resection of the prostate (TURP) and crude rates of PSA testing, Scotland * to the European standard population

© Cancer Research UK 2008 Registered charity number Figure Seven: Diagram of the prostate

© Cancer Research UK 2008 Registered charity number Table Two: Treatment and management options for men with localised disease (adapted with permission from NICE (2008) CG58. Prostate cancer: diagnosis and treatment. London. 8 Low-risk men (PSA < 10ng/ml and Gleason score ≤6 and T1- T2a Intermediate-risk men (PSA ng/ml or Gleason score 7 or T2b-T2c High-risk men (PSA >20 ng/ml or Gleason score 8-10 or T3-T4) Watchful waiting◊◊◊ Active surveillanceü◊X Brachytherapy◊◊X Prostatectomy◊üü*ü* High dose conformal radiotherapy◊ü†ü†ü*† CryotherapyX* High intensity focused ultrasoundX* ü Preferred treatmentX Not recommended ◊ Treatment option X* Not recommended unless as part of a clinical trial comparing use with established interventions ü* Offer if there is a realistic prospect of†neo-adjuvant ± adjuvant hormone therapy (for Gleason score ≥8) long term disease control is recommended

© Cancer Research UK 2008 Registered charity number Figure Eight: Rates of radical prostatectomy and orchidectomy, England, 1991–2004 (Adapted with permission from Hussain S et al. BJU Int 2008;101(5):547–55)

© Cancer Research UK 2008 Registered charity number Figure Nine: Hormone treatment for prostate cancer, UK, 1975–2004 (Adapted with permission from Hussain S et al. BJU Int 2008;101(5):547–55)

© Cancer Research UK 2008 Registered charity number Figure Ten: One, five and ten-year age-standardised relative survival for prostate cancer, men aged diagnosed in England and Wales, 1971–2001

© Cancer Research UK 2008 Registered charity number Figure Eleven: Five-year age-adjusted relative survival, selected countries in Europe and the US,

© Cancer Research UK 2008 Registered charity number Figure Twelve: Relative survival at five years since diagnosis by age, prostate cancer; patients diagnosed , England

© Cancer Research UK 2008 Registered charity number Table Three: Number of deaths and mortality rates of prostate cancer, UK, 2007 EnglandWalesScotlandN.IrelandUK Deaths Males8, ,239 Crude rate per 100,000 population Males Age-standardised rate (European) per 100,000 population Males CI 95%

© Cancer Research UK 2008 Registered charity number Figure Thirteen: Number of deaths and age-specific mortality rates, prostate cancer, UK, 2007

© Cancer Research UK 2008 Registered charity number Figure Fourteen: Age-specific mortality rates, prostate cancer, UK,